Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: February 15, 2018
Expires: February 14, 2019
1 hour to complete

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Simulation-services provided by Syandus

Support Statement

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Activity Chair

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA

Royalty: SLACK Incorporated;
Consulting Fees: Abbott/AbbVie, Actavis, Alaven, Ferring, Hospira, Janssen Orthobiotech, Luitpold/American Regent, Pfizer, Prometheus, Romark, Salix, Santarus, Shire, Takeda, UCB;
Contracted Research: Ferring, Prometheus, Salix, Santarus, Shire, UCB;
Research Grant (paid to institution): Janssen Orthobiotech;
Author Honoraria: McMahon Publishing, Up to Date;
Editor Honoraria: Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media.


Meenakshi Bewtra, MD, PhD, MPH
Assistant Professor of Medicine and Epidemiology
Center for Clinical Epidemiology and Biostatistics
Raymond and Ruth Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Contracted Research: GlaxoSmithKline, Takeda.

Nabeel Khan, MD
Assistant Professor of Clinical Medicine
Raymond and Ruth Perelman School of Medicine
University of Pennsylvania
Director of Gastroenterology
Philadelphia VA Medical Center
Philadelphia, PA

No relevant financial relationships to disclose.


Ronald Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 15, 2018 to February 14, 2019.

How To Participate in this Activity and Obtain CME Credit

  • Read the target audience, learning objectives, and faculty disclosures.
  • Launch the simulation from the link provided on on a PC, Mac, tablet, or plus-size phone.
  • Complete the pretest and launch the first simulation scenario. Interact appropriately to satisfy each objective to unlock the next objective. The simulation will track your progress until all scenario objectives and assessment components are complete. You can exit the simulation and it will save your progress so that you can return to finish at a later time.
  • As you successfully complete more scenarios (2 total), you will qualify for increasing levels of CE credit (ranging from 0.5 to 1.00 credits). Click or tap "Credit" to determine your CE credit status and receive credit. Upon successful completion of the evaluation, you will receive a certificate of credit immediately via the browser.


Inflammatory bowel disease (IBD) is a chronic, frequently progressive condition that affects approximately 1 to 1.3 million people in the United States. Improvement in the care of patients with IBD is needed, as evidenced by a recent study of insurance claims that showed approximately 80% of 32,883 patients with IBD received suboptimal therapy. The outcomes of patients with IBD are diminished by multiple factors, including uncertainty about approaches to diagnosis, assessment, and treatment, as well as a lack of knowledge about available therapies.

To meet the persistent challenges associated with IBD management, health care professionals must be knowledgeable about the evidence-based and expert-recommended strategies for the treatment of patients with IBD to avoid disease flares, prevent structural damage and disability, as well as restore quality of life. In this virtual IBD patient management simulator, an authentic in-office setting with patient interaction will be presented. This simulation will allow authentic practice in the management of a patient with IBD, including determining the appropriate therapy for IBD based on the type and severity.

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the treatment of patients with IBD.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Analyze endoscopic and histologic findings that are characteristic of specific types of inflammatory bowel disease.
  • Apply the safety and efficacy of conventional and new treatments when determining the appropriate therapy for inflammatory bowel disease, based upon type and severity.
  • Incorporate therapeutic drug monitoring, stool markers, and the assessment of mucosal healing in monitoring inflammatory bowel disease as well as in response to treatment, to better predict exacerbations.

Copyright Statement

This CME simulation activity is licensed to Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Copyright © 2018 Syandus Inc and Vindico Medical Education. All rights reserved. No part of this simulation activity may be reproduced without written permission from Vindico Medical Education and Syandus Inc. The material presented in this Vindico Medical Education continuing medical education activity does not necessarily reflect the views and opinions of Vindico Medical Education or Syandus Inc. Neither Vindico Medical Education, Synadus Inc, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.